Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
주식 순위 #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
주가
$62.26
마지막 동기화: 2026-09-22
시가총액
$127.18B
변동 (1일)
-0.78%
변동 (1년)
38.63%
국가
US
거래 Bristol-Myers Squibb Company (BMY)

카테고리

Bristol-Myers Squibb Company (BMY)의 주식 분할 이력
Bristol-Myers Squibb Company 주식 (심볼: BMY)은 총 6회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 07, 2001에 발생했습니다.
May 31, 1977 이전에 매수한 BMY 주식 1주는 현재 33.621320960687주의 BMY 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
2001-08-07 1000000:951777 x1.0506662800215 x33.621320960687
1999-03-01 2:1 x2 x32
1997-03-03 2:1 x2 x16
1987-06-10 2:1 x2 x8
1983-05-27 2:1 x2 x4
1977-05-31 2:1 x2 x2
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
4 x15
US
7 x432
US
0 -
US
2 x10000
CH
7 x226
US